Zerlasiran Was Well Tolerated and Reduced Time-averaged Lp(a) Concentration: The ALPACAR Trial
Key Takeaways: Zerlasiran, a short interfering RNA (siRNA) targeting lipoprotein(a) (Lp(a)), was…
AMULET IDE Trial 5 years Showed Long-term Safety and Efficacy of AMPLATZER Amulet and Watchman Device in LAAO
Key Takeaways: The AMULET IDE trial compared the AMPLATZER Amulet occluder with…
ATTR-Specific Medication and AVR Improve Survival in Patients with Aortic Stenosis and ATTR Cardiac Amyloidosis
Key Takeaways: In this international registry, 266 patients with dual pathology, aortic…
Bempedoic Acid Reduces Major Adverse Limb Events in Patients with PAD : A Pre-specified Analysis from the CLEAR Outcomes Trial
Key Points: Patients with peripheral artery disease (PAD) at an increased risk…
Consistent Efficacy and Safety of Finerenone in Women and Men: A Secondary Analysis of the FINEARTS-HF Trial
KEY POINTS: Historically women have been underrepresented in cardiovascular clinical trials, however,…
Oral Muvalaplin Lowered Lipoprotein(a): The KRAKEN Trial
Key Takeaways: KRAKEN was an international, multicenter, placebo controlled, phase 2 trial…
Rivaroxaban for 18 Months Superior to 6 Months To Prevent Recurrent VTE Events in Cancer Patients with Acute-low PE: ONCO PR
Key Takeaways: The ONCO PE trial demonstrated that an 18-month treatment with…
Promising Cardioprotective Effect of ARNi in High-Risk Cancer Patients Treated with Anthracycline Chemotherapy: SARAH
Key Points: Anthracycline (ANT)-based chemotherapy is a known cancer treatment regimen but…
Semaglutide Improves CV Outcomes in Patients with Prior Coronary Artery Bypass Surgery: Insights from the SELECT Trial
Key Takeaways: In this secondary analysis of the SELECT Trial, semaglutide 2.4…
VALOR-HCM: Mavacamten Reduces Long-Term Need for Septal Reduction Therapy in Symptomatic Obstructive HCM
Key Points: In patients with treatment-refractory symptomatic obstructive hypertrophic cardiomyopathy (HCM), invasive…
FLOW Trial: Renal Benefits of Semaglutide in T2DM Similar Regardless of Baseline CV Risk
Key Points Both chronic kidney disease (CKD) and cardiovascular disease (CVD) are…
Reconditioned Pacemakers Non-Inferior To New Pacemakers in Low- and Middle-Income Countries: Preliminary Results from My Heart Your Heart Trial
Key Points: Many patients in low- and middle-Income countries are unable to…
Linear Ablation Combined with EIVOM Provides Additional Benefit in Rhythm Outcomes for Persistent AF Ablation: PROMPT-AF Trial
Key Points: It is unknown if linear ablation with ethanol infusion of…
Metformin and Aggressive Lifestyle Modifications Reduce AF Fibrillation Symptoms but Not Burden: Results From the TRIM-AF Trial
Key Points: Despite prior data suggesting decrease in metabolic stress may reduce…
SUMMIT Subanalysis: Tirzepatide Reduces Symptom Burden in Patients with Obesity-Related HFpEF
Key Points Patients with heart failure with preserved ejection fraction (HFpEF) and…
In a Hierarchical Composite Outcome, Finerenone Shows Reduction in HF Exacerbations in HFmrEF or HFpEF: FINEARTS
KEY POINTS: Hierarchical analysis prioritizing significant events more effectively traditional composite outcomes,…
Finerenone Raises Potassium but Retains Clinical Benefits with Protocol-directed Surveillance and Dose Adjustment: FINEARTS
KEY POINTS: Finerenone, a non-steroidal mineralocorticoid (MRA), increased serum potassium levels more…
HELIOS-B trial – Vutrisiran Reduces Risk of Outpatient Worsening Heart Failure in ATTR-CM in a subgroup analysis
Key Points: Transthyretin amyloidosis (ATTR-CM) is a fatal disease caused by the…
ARREST-AF: Aggressive Risk Factor Management After AF Ablation Reduces Arrythmia Recurrence at 12 Months
Key Points Observation data has suggested that improving cardiometabolic risk factors after…
SUMMIT CMR: Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related HFpEF
Key Points Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated…